2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Haifaa Abdulhaq, MD, discusses the benefits of chemotherapy-free options in diffuse large B-cell lymphoma.
Haifaa Abdulhaq, MD, an associate clinical professor in Hematology and Oncology at the University of California, San Francisco (UCSF) and the director of hematology and the Hematology/Oncology Fellowship Program at UCSF Fresno, discusses the benefits of chemotherapy-free options in diffuse large B-cell lymphoma (DLBCL).
There is something to be said about the safety profile of tafasitamab and how it helps patients maintain quality of life, says Abdulhaq. Patients who have relapsed/refractory DLBCL and are transplant ineligible, are often older or have comorbidities. In this patient population, maintaining a balance between efficacy and a reasonable toxicity profile is essential, according to Abdulhaql; this is a benefit provided with tafasitamab. Lenalidomide (Revlimid) is another important chemotherapy-free, oral agent that provides value to these patients, concludes Abdulhaq.
Related Content: